In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Company PLC

http://www.perrigo.com/

Latest From Perrigo Company PLC

Consumers’ Inflation Fatigue, Recession Fears May Put Health, Beauty Product Price Increases On Hold

Church & Dwight, Perrigo executives' comments at investor conferences could signal OTC drug, supplement and personal care product firms are moving from gauging pandemic impact on supply chains and consumer spending to anticipating shifts in consumer preferences and cost increases caused by inflation with recession appearing more likely every day.

Consumer Coronavirus COVID-19

Abbott Among Firms Gaining Formula Import Approvals As Flood Closes Its Michigan Plant

Two days before flooding closed its Sturgis plant, Abbott announced it would import 1.1m pounds of powder formula to the US from its manufacturing facility in Spain.  

Consumer FDA

HBW Executive Decisions: Perrigo CFO Joins Neptune Wellness, Athletes Promote Wellness Products, More

Perrigo CFO has 10-dy break before starting at Neptune Wellness ; CHPA board elects Lisa Paley as chair, Ian Thorpe joins Anthogenol team; Shreyas Iyer advertises Ultrahuman wearable; HRG expands business sectors with Corey Paske; and DFE Pharma hires Marie-Louise Mans as HR director. 

Executive Changes Consumer

AMA Shares OTC Birth Control Diagnosis With FDA

American College of Obstetricians and Gynecologists proposed amending existing AMA policy in anticipation of Perrigo’s HRA business submitting NDA to FDA for OTC switch of progestin-only daily oral contraceptive the end of 2022.

Prescription To OTC Switch FDA
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Agis Industries
    • Chemagis
    • Clay-Park Labs
    • Cobrek Pharmaceuticals
    • Elan Corporation
    • JB Laboratories
    • Onclave Therapeutics Limited
    • Omega Pharma Invest N.V.
    • Paddock Laboratories
    • Omega Pharma Invest N.V.
    • Ranir Global Holdings LLC
    • Rosemont Pharmaceuticals Ltd.
    • Unico Holdings Inc.
    • Velcera, Inc.
    • Geiss, Destin & Dunn, Inc.
    • High Ridge Brands
UsernamePublicRestriction

Register